Capivasertib Cost-Effectiveness in Advanced Breast Cancer

By Rene Pretorius

April 18, 2025

Capivasertib, a novel AKT inhibitor, has gained approval as a second-line therapy for advanced breast cancer, but its high cost has sparked concerns about its economic viability. This review summarizes the results of the first published economic evaluation of Capivasertib in a cost-effectiveness study among patients with PIK3CA/AKT1/PTEN-altered, hormone receptor-positive (HR+), HER2-negative advanced breast cancer.

Key Insights:

  • The study used a Markov model to compare three treatments. These included capivasertib plus fulvestrant for all patients, for postmenopausal women only, and fulvestrant alone.
  • The incremental cost-effectiveness ratio for capivasertib plus fulvestrant was $280,854 per QALY. This exceeds the $100,000/QALY threshold.
  • To be cost-effective, capivasertib’s price would need a 70% reduction, lowering it to $7,000 per cycle.

Evaluating Capivasertib´s Economic Value

The study evaluates capivasertib combined with fulvestrant for advanced breast cancer. It compares three approaches: capivasertib with fulvestrant for all patients, only for postmenopausal women, or fulvestrant alone. The model uses a U.S. payer perspective with 2023 dollars. It measures benefits in life years and quality of life over a patient’s lifetime. Multiple scenarios confirm the findings’ reliability. Adding capivasertib for all patients increases costs by $410,765 and extends quality life by 1.46 years. This yields a cost of $280,854 per quality life year gained. Restricting capivasertib to postmenopausal women proved less effective and remained overly expensive. These conclusions were consistent across multiple tested scenarios.

Pricing and Access Implications

Capivasertib’s high price creates access barriers for advanced breast cancer treatment. Its cost-effectiveness ratio of $280,854 per quality-adjusted life year exceeds the $100,000 threshold. This makes it unaffordable for many payers. A 70% price cut to $7,000 per cycle could align costs with benefits. This would improve access for patients with PIK3CA/AKT1/PTEN-altered, HR+/HER2− breast cancer. High costs may reduce use, especially in resource-limited settings. This could widen treatment disparities. Payers and manufacturers should consider value-based pricing or patient assistance programs to enhance affordability while leveraging the drug’s benefits.

In summary, capivasertib offers clinical value but costs too much. Pricing changes are essential to broaden access to this therapy.

For more details, refer to the study in SpringerLink.

Reference url

Recent Posts

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

marstacimab hemophilia B
                

NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment Landscapes and Economic Implications

💡 Are we witnessing a paradigm shift in hemophilia treatment?

The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.

Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.

Explore the full article for deeper insights!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

HPV-related cancer trends
    

HPV-Related Cancer Trends in South Africa 2011-2021

🌍 Are we witnessing a rise in HPV-related cancer in South Africa?

A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.

Dive into the findings and explore the implications for health systems and policies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.